Monthly Archives: January 2015

Genome Project legacy: advancements in gene th – Video

Posted: January 8, 2015 at 3:47 am


Genome Project legacy: advancements in gene th
KFDM #39;s Six On Health, sponsored by Christus Hospital St. Elizabeth #39;s and St. Mary explores how they Human Genome Project #39;s effort to map our chromosomal makeup has led to advances in gene ...

By: KFDM YouTube

More:
Genome Project legacy: advancements in gene th - Video

Posted in Genome | Comments Off on Genome Project legacy: advancements in gene th – Video

Genome wide expression changes in vascular tissue identified due to infection/diet

Posted: at 3:47 am

Although it has been shown that a diet high in fat and exposure to certain bacteria can cause atherosclerosis (the buildup of fats, cholesterol and other substances on artery walls which can restrict blood flow), researchers have for the first time identified distinct gene pathways that are altered by these different stimuli. These findings, which currently appear in BMC Genomics, suggest that future therapies for this disease may need to be individualized.

Atherosclerosis is a common human disease associated with heart attack and stroke. Certain bacteria as well as high fat diet are associated with an increased risk for atherosclerosis. One of these bacteria, Porphyromonas gingivalis, is found in the mouth of humans with periodontal disease; another, Chlamydia pneumoniae, causes pneumonia.

In this study, the researchers used four experimental groups to compare genome-wide expression changes in vascular tissue. The first group was subjected to Porphyromonas gingivalis while the second group received Chlamydia pneumoniae. The third group was placed on a high-fat diet while the fourth group was the control. In collaboration with the Clinical and Translational Science Institute (CTSI) at Boston University, the researchers performed genome-wide microarray profiling and analysis of vascular tissue from all groups to reveal gene pathways altered in the atherosclerotic plaque by each treatment group.

"Given the prevalence of diet-induced obesity and infection with Porphyromonas gingivalis and Chlamydia pneumoniae in the general population and the likelihood of co-morbidity of obesity with chronic or recurring infection with these common pathogens, these findings suggest that the development of atherosclerosis in humans is likely more complex and multifactorial than previously appreciated," explained senior author Caroline Attardo Genco, PhD, professor of medicine and microbiology at BUSM. "These findings may explain how specific infections or a high-fat diet may cause atherosclerotic plaques to undergo changes which affect their size and stability and may ultimately lead to a heart attack," she added.

Story Source:

The above story is based on materials provided by Boston University Medical Center. Note: Materials may be edited for content and length.

See more here:
Genome wide expression changes in vascular tissue identified due to infection/diet

Posted in Genome | Comments Off on Genome wide expression changes in vascular tissue identified due to infection/diet

200-Year-Old Whale May Give Clues to Human Longevity

Posted: at 3:46 am

Latest Senior Health News

TUESDAY, Jan. 6, 2015 (HealthDay News) -- A whale that lives more than 200 years with no signs of age-related disease may give scientists new insight on how people can live longer, healthier lives, a new study finds.

For the first time, British researchers have completed the genetic map ("genome") of a large whale -- the bowhead whale. In doing so, they spotted key differences between the genome of the bowhead whale and other mammals.

Changes in the bowhead's genes tied to aging, cell division, cancer and DNA repair may all play a role in why the whales live so long, according to the study published Jan. 6 in Cell Reports.

"Our understanding of species' differences in longevity is very poor, and thus our findings provide novel candidate genes for future studies," study senior author Dr. Joao Pedro de Magalhaes, of the University of Liverpool, said in a journal news release.

"My view is that species evolved different 'tricks' to have a longer lifespan, and by discovering the 'tricks' used by the bowhead we may be able to apply those findings to humans in order to fight age-related diseases," he added.

The researchers pointed out that large whales like the bowhead have more than 1,000 times more cells than people, and yet they appear to be resistant to cancer. This suggests that these whales may have a natural defense mechanism that suppresses cancer more effectively than other mammals, they said.

Looking ahead, the study authors hope to breed mice with certain bowhead whale genes to determine which are important for longevity and resistance to disease.

The whale genome may also help identify certain adaptations related to the large mammal's size, such as a much lower metabolic rate.

-- Mary Elizabeth Dallas

Excerpt from:
200-Year-Old Whale May Give Clues to Human Longevity

Posted in Human Longevity | Comments Off on 200-Year-Old Whale May Give Clues to Human Longevity

Chief Keef Tweakin With Ballout: You Got Eczema? – Video

Posted: at 3:46 am


Chief Keef Tweakin With Ballout: You Got Eczema?
Chief Keef Tweakin With Ballout: You Got Eczema? Follow: http://instagram.com/tevindinero Stay Updated Follow: https://twitter.com/iGotTheDirt.

By: iGotTheDirt

Read more from the original source:
Chief Keef Tweakin With Ballout: You Got Eczema? - Video

Posted in Eczema | Comments Off on Chief Keef Tweakin With Ballout: You Got Eczema? – Video

Chief Keef Clownin’ On Ballout: You Got Eczema? (Extended Version) – Video

Posted: at 3:46 am


Chief Keef Clownin #39; On Ballout: You Got Eczema? (Extended Version)
Chief Keef Clownin #39; On Ballout: You Got Eczema? (Extended Version) Part 1,2, 3. Subscribe.

By: WorldStar Tv

Excerpt from:
Chief Keef Clownin' On Ballout: You Got Eczema? (Extended Version) - Video

Posted in Eczema | Comments Off on Chief Keef Clownin’ On Ballout: You Got Eczema? (Extended Version) – Video

Defeat Eczema Today Review [INSIDE LOOK! Shocking truth revealed!] – Video

Posted: at 3:46 am


Defeat Eczema Today Review [INSIDE LOOK! Shocking truth revealed!]
Defeat Eczema Today Review http://defeateczematoday.org/eczema Defeat Eczema Today Review Defeat Eczema Today by Ellie Caroll is a natural treatment to cure eczema forever. For those who are ...

By: Home Power Experts

Go here to see the original:
Defeat Eczema Today Review [INSIDE LOOK! Shocking truth revealed!] - Video

Posted in Eczema | Comments Off on Defeat Eczema Today Review [INSIDE LOOK! Shocking truth revealed!] – Video

Psoriasis Diet Diary Week Fifteen & Sixteen – Video

Posted: at 3:46 am


Psoriasis Diet Diary Week Fifteen Sixteen
Here it is folks! Not a great couple of weeks for skin, with Xmas food and peer pressure at every turn. I #39;ve done really well and only had the odd thing, but...

By: Jon Maddison

Continued here:
Psoriasis Diet Diary Week Fifteen & Sixteen - Video

Posted in Psoriasis | Comments Off on Psoriasis Diet Diary Week Fifteen & Sixteen – Video

Review article estimates annual US cost of psoriasis in 2013

Posted: at 3:46 am

The annual U.S. cost of psoriasis, a chronic inflammatory skin condition, was estimated to be between $112 billion and $135 billion in 2013, according to a review article published online by JAMA Dermatology.

Psoriasis affects about 3.2 percent of the U.S. population and understanding the economic burden of the disease is important for research, advocacy and educational efforts.

Elizabeth A. Brezinski, M.D., of the University of California, Davis, Sacramento, and coauthors reviewed 22 studies to estimate the direct, indirect, intangible and comorbidity costs of adult psoriasis. The results were adjusted to 2013 dollars.

Their review found direct psoriasis costs ranged from $51.7 billion to $63.2 billion, while indirect costs (due to absenteeism or going to work while sick) ranged from $23.9 billion to $35.4 billion. Medical comorbidities were estimated to contribute another $36.4 billion. And intangible costs (to eliminate the negative effects of psoriasis in physical and mental health) amounted to a one-time cost of up to $11,498 per patient with psoriasis, according to the review results.

"The direct health care costs are significantly greater for patients with psoriasis than for the general population and are also higher for patients with increasing psoriasis disease severity. Defining the economic burden of psoriasis from a societal perspective is the foundation for innovating and providing access to cost-effective therapies that will result in improved patient outcomes," the authors note.

Story Source:

The above story is based on materials provided by The JAMA Network Journals. Note: Materials may be edited for content and length.

Original post:
Review article estimates annual US cost of psoriasis in 2013

Posted in Psoriasis | Comments Off on Review article estimates annual US cost of psoriasis in 2013

CU School of Medicine's April Armstrong estimates cost of psoriasis in the US

Posted: at 3:46 am

AURORA, Colo. (Jan. 7. 2015) - The annual U.S. cost of psoriasis, a chronic inflammatory skin condition, was estimated to be between $112 billion and $135 billion in 2013, according to a review article published online by JAMA Dermatology.

Psoriasis affects about 3.2 percent of the U.S. population and understanding the economic burden of the disease is important for research, advocacy and educational efforts.

April Armstrong, MD, MPH, associate professor and vice chair of clinical research in the Department of Dermatology at the University of Colorado School of Medicine, is the senior and corresponding author of the article. Armstrong, along with co-authors, reviewed 22 studies to estimate the direct, indirect, intangible and comorbidity costs of adult psoriasis. The results were adjusted to 2013 dollars.

Their review found direct psoriasis costs ranged from $51.7 billion to $63.2 billion, while indirect costs (due to absenteeism or going to work while sick) ranged from $23.9 billion to $35.4 billion. Medical comorbidities were estimated to contribute another $36.4 billion. And intangible costs (to eliminate the negative effects of psoriasis in physical and mental health) amounted to a one-time cost of up to $11,498 per patient with psoriasis, according to the review results.

"The direct health care costs are significantly greater for patients with psoriasis than for the general population and are also higher for patients with increasing psoriasis disease severity. ... Defining the economic burden of psoriasis from a societal perspective is the foundation for innovating and providing access to cost-effective therapies that will result in improved patient outcomes," the authors note.

The article is published online today.

###

About the University of Colorado School of Medicine

Faculty at the University of Colorado School of Medicine work to advance science and improve care. These faculty members include physicians, educators and scientists at University of Colorado Health, Children's Hospital Colorado, Denver Health, National Jewish Health, and the Denver Veterans Affairs Medical Center. The school is located on the Anschutz Medical Campus, one of four campuses in the University of Colorado system. To learn more about the medical school's care, education, research and community engagement, visit its web site.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

Go here to see the original:
CU School of Medicine's April Armstrong estimates cost of psoriasis in the US

Posted in Psoriasis | Comments Off on CU School of Medicine's April Armstrong estimates cost of psoriasis in the US

Novartis: Gene editing is new frontier

Posted: at 3:46 am

Wednesday, January 07 11:43:20

Novartis is diving deeper into the world of gene-based medicine by signing deals with two U.S. biotech companies, giving it access to a powerful new genome editing technology.

The tie-ups with unlisted Intellia Therapeutics and Caribou Biosciences show the Swiss drugmaker's confidence in the potential of so-called CRISPR technology, both for making new medicines and as a research tool.

CRISPR, which stands for clustered regularly interspaced short palindromic repeats, allows scientists to edit the genes of selected cells accurately and efficiently. It has created great excitement since emerging two years ago and is being tipped for a Nobel Prize.

While current gene therapy approaches involve adding genes to affected cells, CRISPR opens up the possibility of correcting those cells' faulty genes in the lab before returning them to the patient.

Translating that promise into new treatments will take many years but Novartis' decision to apply the technology in its research labs is an important endorsement, since the company is the world's largest drugmaker by sales.

It is also a sign the Swiss group intends to be at the forefront of the nascent field, after recently establishing a new cell and gene therapies unit within the company.

Mark Fishman, head of the Novartis Institutes for BioMedical Research (NIBR), said genome editing could open a new branch of medicine, leading to cures for diseases caused by faulty genes.

"We have glimpsed the power of CRISPR tools in our scientific programmes in NIBR and it is now time to explore how to safely extend this powerful technology to the clinic," he said.

The deal with Intellia gives Novartis exclusive rights to develop programmes focused on engineered chimeric antigen receptor T-cells (CARTs) and the right to develop a certain number of targets for editing hematopoietic stem cells.

Continue reading here:
Novartis: Gene editing is new frontier

Posted in Gene Medicine | Comments Off on Novartis: Gene editing is new frontier